A hemodialysis patient with higher-risk myelodysplastic syndrome treated with standard-dose azacitidine

Leuk Lymphoma. 2012 Dec;53(12):2521-2. doi: 10.3109/10428194.2012.688201. Epub 2012 May 21.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Azacitidine / therapeutic use*
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Male
  • Methyltransferases / antagonists & inhibitors
  • Myelodysplastic Syndromes / complications
  • Myelodysplastic Syndromes / drug therapy*
  • Polycystic Kidney Diseases / complications
  • Polycystic Kidney Diseases / therapy
  • Renal Dialysis*
  • Risk Factors
  • Treatment Outcome

Substances

  • Enzyme Inhibitors
  • Methyltransferases
  • Azacitidine